Investor Presentaiton

Strong business momentum Diversified portfolio growth Efficient compounding engine Sustainable long-term growth Established growth portfolio provides a strong foundation Adjusted Cash Receipts (1) ("top-line") ~$1,800m Key therapies Therapy Marketer(s) 2021 market position (3) 2025e sales(4) Cystic fibrosis franchise(2) Vertex #1 for cystic fibrosis ~$10bn CAGR: ~3% ~$2,000-2,200m imbruvică AbbVie J&J #1 for chronic lymphocytic leukemia ~$7bn Xtandi Astellas Pfizer #1 for prostate cancer ~$5bn Key expiries: - HIV franchise - Januvia/Janumet Lexiscan Key drivers: + CF franchise (1) + Tremfya + Cabometyx + Tysabri 2020 Expiries Growth 2025e Tremfya J&J #5 for psoriasis ~$5bn CABOMETYX Exelixis Ipsen Takeda #1 tyrosine kinase inhibitor for renal cell carcinoma ~$3bn TYSABRI Biogen #2 high efficacy therapy for multiple sclerosis ~$2bn ROYALTY PHARMA 1. See slide 114 for definitions and factors that may impact the achievement of our growth outlook. 2. Cystic fibrosis franchise includes Trikafta, Symdeko, Orkambi, and Kalydeco. 3. Based on 2021 actual sales. 4. Based on Visible Alpha consensus as of May 9, 2022. 90 90

View entire presentation